Prognostic value of prostate volume in non-muscle invasive bladder cancer

There is evidence that a history of benign prostatic hyperplasia increases the incidence of bladder cancer, and treatment with 5-alpha reductase inhibitor or androgen deprivation therapy reduces recurrence of non-muscle invasive bladder cancer. We aimed to evaluate whether prostate volume affects it...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-09, Vol.11 (1), p.18784-18784, Article 18784
Main Authors: Ham, Won Sik, Park, Jee Soo, Jang, Won Sik, Choi, Young Deuk, Kim, Jongchan
Format: Article
Language:English
Subjects:
631/67/589/1336
692/699/2768/1753
Aged
Bladder cancer
Cancer
Cancer therapies
Chemotherapy
Computed tomography
Humanities and Social Sciences
Humans
Hyperplasia
Invasiveness
Male
Medical prognosis
Medical records
Middle Aged
multidisciplinary
Organ Size
Patients
Prognosis
Propensity Score
Prostate
Prostate - diagnostic imaging
Prostate - pathology
Prostatic Hyperplasia - mortality
Prostatic Hyperplasia - pathology
Regression analysis
Science
Science (multidisciplinary)
Survival
Survival Analysis
Tomography, X-Ray Computed
Treatment Outcome
Tumors
Urinary Bladder Neoplasms - diagnosis
Urinary Bladder Neoplasms - mortality
Urinary Bladder Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is evidence that a history of benign prostatic hyperplasia increases the incidence of bladder cancer, and treatment with 5-alpha reductase inhibitor or androgen deprivation therapy reduces recurrence of non-muscle invasive bladder cancer. We aimed to evaluate whether prostate volume affects its prognosis. We reviewed medical records of men who underwent transurethral resection of bladder tumor due to non-muscle invasive bladder cancer from January 2012 to December 2017. Patients were divided into two groups based on prostate volume measured by computed tomography (group 1: 264 patients with ≤ 30 mL, group 2: 124 patients with > 30 mL). Propensity score matching analysis was used for adjust selection bias, and then assessed recurrence-free survival and progression-free survival. With a median follow up duration of 52 months, group 1 showed higher 5-year recurrence-free and progression-free survival (69.3% vs 47.0%, p = 0.001; 96.7% vs 87.7%, p = 0.002). Further, cox-regression analysis showed that tumor size (HR = 1.292 p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-98045-1